7JTY
Co-crystal structure of alpha glucosidase with compound 1
Summary for 7JTY
Entry DOI | 10.2210/pdb7jty/pdb |
Descriptor | Alpha glucosidase 2 alpha neutral subunit, Glucosidase 2 subunit beta, (1S,2S,3R,4S,5S)-5-(butylamino)-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol, ... (8 entities in total) |
Functional Keywords | alpha glucosidase ii, endoplasmic reticulum, inhibitor complex, hydrolase |
Biological source | Mus musculus (Mouse) More |
Total number of polymer chains | 4 |
Total formula weight | 346139.20 |
Authors | Karade, S.S.,Mariuzza, R.A. (deposition date: 2020-08-18, release date: 2021-10-13, Last modification date: 2024-10-23) |
Primary citation | Karade, S.S.,Hill, M.L.,Kiappes, J.L.,Manne, R.,Aakula, B.,Zitzmann, N.,Warfield, K.L.,Treston, A.M.,Mariuzza, R.A. N-Substituted Valiolamine Derivatives as Potent Inhibitors of Endoplasmic Reticulum alpha-Glucosidases I and II with Antiviral Activity. J.Med.Chem., 64:18010-18024, 2021 Cited by PubMed Abstract: Most enveloped viruses rely on the host cell endoplasmic reticulum (ER) quality control (QC) machinery for proper folding of glycoproteins. The key ER α-glucosidases (α-Glu) I and II of the ERQC machinery are attractive targets for developing broad-spectrum antivirals. Iminosugars based on deoxynojirimycin have been extensively studied as ER α-glucosidase inhibitors; however, other glycomimetic compounds are less established. Accordingly, we synthesized a series of N-substituted derivatives of valiolamine, the iminosugar scaffold of type 2 diabetes drug voglibose. To understand the basis for up to 100,000-fold improved inhibitory potency, we determined high-resolution crystal structures of mouse ER α-GluII in complex with valiolamine and 10 derivatives. The structures revealed extensive interactions with all four α-GluII subsites. We further showed that N-substituted valiolamines were active against dengue virus and SARS-CoV-2 . This study introduces valiolamine-based inhibitors of the ERQC machinery as candidates for developing potential broad-spectrum therapeutics against the existing and emerging viruses. PubMed: 34870992DOI: 10.1021/acs.jmedchem.1c01377 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (2.21 Å) |
Structure validation
Download full validation report